Hexvix Photodynamic Therapy in Patients With Bladder Cancer

Inclusion Criteria: * Male or female aged 18 years or above who have given written informed consent. * Patients with intermediate or high-risk superficial bladder cancer, defined as low-grade early recurrence within 6 months after local chemotherapy or BCG, primary or recurrent high-grade disease (TaG3, TaG3 with CIS or CIS alone) or patients with primary T1G3 who are tumour free at second resection. Exclusion Criteria: * Patients with muscle invasive tumour * Patients with bladder shrinkage * Patients who have received prior PDT for bladder cancer * History of T1G3 disease or other indications for cystectomy * Patient with porphyria * Gross haematuria. (Note: Gross haematuria is defined as a heavy bladder bleed resulting in marked amounts of blood in the urine, which may interfere with PDT) * Patients who have received BCG or chemotherapy within three months prior to Hexvix instillation, except for a single dose of chemotherapy for prevention of seeding after resection * Known allergy to hexaminolevulinate or a similar compound * Participation in other clinical studies either concurrently or within the last 30 days * Women of child-bearing potential. * Conditions associated with a risk of poor protocol compliance